Healthcare Business

buy sell

Why Investors Are Not Chasing Gilead Endlessly Higher

By any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue estimates. Its ...
Read Full Story »
Stock Split Image

Lombard Signals More Evidence of IPO Market Reality Check

The market for initial public offerings was getting to be a bit ridiculous. Now that volatility has returned in the broader stock market, a reality check is starting to be ...
Read Full Story »
biotech

Companies Betting on the Next 10 Blockbuster Drugs

The biotech sector has seen its valuations hit hard in many cases in 2014, but many investors remain excited about the future wave of big biotech drugs -- and big ...
Read Full Story »
DNA

UBS Top Stocks to Buy Working for Cancer Cures

Cancer is the leading cause of death globally, and a disease that touches almost every person in our nation one way or another. In a new research report, the Healthcare ...
Read Full Story »
biotech

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Gilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild ...
Read Full Story »
Biotechnology word cloud

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

Biotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is ...
Read Full Story »
cannabis

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

GW Pharmaceuticals PLC (NASDAQ: GWPH) is far from your typical pharma or biotech stock. It is also far from your typical legalized marijuana or medical marijuana stock. That being said, ...
Read Full Story »
Pills

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. The biggest is the possible deal between activist hedge fund manager Bill Ackman's Pershing Square, Valeant ...
Read Full Story »
biotech

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

It is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion ...
Read Full Story »
Pills

Odds of Sarepta Drug Approval Rise Sharply

Shares of drugmaker Sarepta Therapeutics Inc. (NASDAQ: SRPT) went through the roof Monday morning following an announcement that the company plans to have a New Drug Application (NDA) filed with ...
Read Full Story »
DNA

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Since March 4, the biotech index is off a massive 19%. There has been plenty of Wall Street speculation on why the sell-off was so violent, but at the end ...
Read Full Story »
145922793

UnitedHealth Group Revenues Stung by Obamacare

UnitedHealth Group Inc. (NYSE: UNH) reported first-quarter results before markets opened Thursday. The health insurance and benefits management firm posted diluted earnings per share (EPS) of $1.10 on revenues of ...
Read Full Story »
health care

Medical Device Maker’s IPO a Modest Success

Some initial public offerings (IPOs) are considered a huge success if the stock appreciates more than about 20% on its IPO date. To some, though, that's an unsuccessful launch from ...
Read Full Story »
95992888

Why Lpath Could Rise 300%

Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes the price target upside is off the charts as well. ...
Read Full Story »
Johnson & Johnson Logo

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson (NYSE: JNJ) reported first-quarter results before markets opened Tuesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.54 on revenue of $18.1 ...
Read Full Story »